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Telomerase Inhibitor Imetelstat in Essential Thrombocythemia 
and Myelofibrosis
To the Editor: Baerlocher et al. (Sept. 3 issue)1 
report on telomere-targeted treatment with im-
etelstat in 18 patients with essential thrombocy-
themia. The drug was effective in controlling 
platelet levels in all patients, albeit often at the 
expense of hemoglobin and neutrophil levels. 
However, the other main treatment goals in es-
sential thrombocythemia2 — controlling symp-
toms and preventing both disease progression 
and thromboembolic complications — were def-
initely not achieved. Fatigue, diarrhea, and nau-
sea were all reported by more than 70% of the 
patients. A total of 3 patients had progression to 
myelofibrosis, and 2 patients had a thromboem-
bolic event. Thus, treatment with imetelstat does 
not seem to be promising in this relatively be-
nign disease.
Only 4 patients had received interferon before 
undergoing this experimental therapy. Pegylated 
interferon alfa-2 is effective in controlling throm-
bocytosis in most patients, and it is not associ-
ated with myelofibrotic transformation, leuke-
mogenicity, or other adverse long-term events.3 
Furthermore, interferon may induce a deep mo-
lecular remission (i.e., a very low JAK2 V617F 
mutation level) and normalization of bone mar-
row changes, effects that in some patients may 
be maintained years after treatment cessation.3,4 
In Denmark, interferon is suggested as first-line 
treatment in patients with essential thrombocy-
themia.5
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To the Editor: In their editorial on the findings 
of Baerlocher et al. and Tefferi et al. (Sept. 3 is-
sue),1 Armanios and Greider2 suggest that the 
experimental drug imetelstat may change the 
natural course of myeloproliferative neoplasms, 
possibly by binding to cell-surface receptors such 
as toll-like receptor 9 (TLR9). Since TLR9 induc-
es the production of type I interferons by plasma-
cytoid dendritic cells,3 it is tempting to speculate 
that the effect may be mediated through inter-
feron alfa-2, which in several studies during the 
past 25 years has proved to be highly effective 
and safe in the treatment of myeloproliferative 
neoplasms with the induction of complete hema-
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tologic remission.4 In a subgroup of patients, 
deep molecular remissions with a reduction in 
JAK2 V617F mutant alleles and normalization of 
the bone marrow were sustained even years after 
the discontinuation of interferon alfa-2, findings 
that are compatible with “minimal residual dis-
ease.”5 Thus, interferon alfa-2 may change the 
natural course of myeloproliferative neoplasms if 
the drug is initiated at the time of diagnosis.4 
Given the toxic side effects and modest treatment 
response associated with imetelstat, we do not 
think this drug can be considered as an alterna-
tive to interferon alfa-2, which in addition to its 
immune-modulating effects is a telomerase in-
hibitor as well.6
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Dr. Baerlocher and colleagues reply: Our 
phase 2 study of imetelstat enrolled 18 patients 
with essential thrombocythemia with a median 
interval of 7 years since initial diagnosis. All the 
patients had received a median of two previous 
therapies, including hydroxyurea, anagrelide, and 
interferon. Although interferon is used in pa-
tients with essential thrombocythemia, this dis-
order is not an approved indication. A total of 
4 patients in our study were previously treated 
with interferon; 1 had resistance, and 3 had un-
acceptable side effects. All 4 of these patients 
had a hematologic response to imetelstat, and 
2 of the 3 patients with mutations had a molecu-
lar response.
Rapid, substantial hematologic and molecular 
responses that were observed in such patients 
provided evidence of anticlonal activity and 
proof-of-concept data for further investigation of 
imetelstat in patients with advanced myeloid 
cancers. The interpretation of data with respect 
to progression to myelofibrosis and thromboem-
bolic events in patients with long treatment his-
tories is difficult from this single-group study. 
Randomized clinical studies are required to com-
pare such end points. Furthermore, complete and 
partial remissions, including reversal of bone 
marrow fibrosis and molecular responses, were 
recently reported in the study by Tefferi et al.
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Dr. Tefferi replies: It is true that imetelstat may 
not have the side-effect profile that justifies its 
further consideration for the treatment of essen-
tial thrombocythemia, as reported by Baerlocher 
et al. However, drug benefit–risk assessment is 
best accomplished in the context of randomized 
studies and should not be surmised from the re-
sults of a small proof-of-concept study. The same 
holds true for other drugs for the treatment of 
essential thrombocythemia, including interferon 
alfa. Treatment-induced reduction in the JAK2 or 
CALR mutant allele burden in patients with es-
sential thrombocythemia has been observed 
with imetelstat, interferon alfa,1 and busulfan.2 
Such observations do not necessarily imply that 
each of these drugs has the same effect on coex-
istent disease clones with different mutations3 or 
an advantage in terms of meaningful health out-
come; the latter requires evidence from controlled 
studies and not conjecture based on local treat-
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ment practices. The observations from our pilot 
study of imetelstat support a unique mechanism 
of action that deserves further laboratory-based 
investigation.
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Cell-free DNA Analysis for Noninvasive Examination of Trisomy
To the Editor: Norton et al. (April 23 issue)1 
report near-perfect accuracy of detection for tri-
somy 21 (Down’s syndrome) with the use of cell-
free DNA (cfDNA) (sensitivity, 100% [38 of 38 
cases of trisomy 21]; false positive rate, 0.06% 
[9 false positives among 15,841 women]) in the 
Noninvasive Examination of Trisomy (NEXT) 
study. These seemingly promising results may be 
misleading because they excluded 488 patients 
(3% of their sample) with indeterminate cfDNA 
results. The prevalence of aneuploidy was higher 
among these patients than in the overall cohort 
(2.7% vs. 0.4%); thus, their exclusion may intro-
duce bias.2 Estimates of accuracy should consider 
indeterminate results to be either positives or 
negatives according to how they would be han-
dled in clinical practice.2
Given their increased risk of aneuploidy, pa-
tients with indeterminate results would probably 
undergo additional testing. Thus, it may be ap-
propriate to classify their cfDNA results as posi-
tives. This classification would result in a false 
positive rate of 3.0% and a positive predictive 
value of 7.6%, much lower than the reported 
positive predictive value of 80.9%. Alternatively, 
if indeterminate results were classified as nega-
tives, sensitivity would be reduced to 38 of 41 cases 
(93%) (95% confidence interval [CI], 80 to 98). 
Assuming that no patients with indeterminate 
results on standard screening had trisomy 21, 
the sensitivity of cfDNA testing and standard 
screening (33 of 41 cases [81%]; 95% CI, 66 to 
90) would not be significantly different (P = 0.22 
by McNemar’s test).
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To the Editor: Norton and colleagues found 
that cfDNA testing for trisomy 21, as compared 
with standard screening, had a better global per-
formance during the first trimester of pregnan-
cy. However, they did not provide information 
about the 14 fetal chromosomal abnormalities in 
the 15,841 screened pregnancies, other than for 
trisomies 13, 18, and 21.
Were these 14 aneuploidies diagnosed prena-
tally because of abnormal features on follow-up 
ultrasonography or because of stillbirths or mis-
carriages? Or were they detected by standard 
screening or postnatally? The answers to these 
questions may help to determine whether a rou-
tine policy of general screening for aneuploidy 
with the use of ultrasonography and cfDNA test-
ing rather than standard screening is the best 
strategy.
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